The DOEA (Enrichr/DGIdb Drug Targets 2024) of the combined CRC cohorts confirmed the enrichment of multiple tyrosine kinase inhibitors in the NFS1/2-high subsets of CRC. Here, NFS1 is linked to colorectal carcinoma.